Oncology-focused digital well being firm Flatiron Well being introduced it entered right into a strategic partnership with Large Bio, an organization that helps most cancers sufferers discover and enroll in medical trials.
Flatiron Well being is an oncology-focused well being know-how firm that provides a platform geared toward optimizing the medical trial course of, together with deciding on trial websites and figuring out sufferers who’re eligible for trials. The corporate additionally offers digital well being report companies and medical determination assist instruments to suppliers.
Large Bio makes use of AI to establish most cancers sufferers eligible for medical trials and join them and their medical doctors to relevant trials.
Flatiron will use Large Bio’s database on a per-study foundation to seek out sufferers who are usually not enrolled in medical trials however dwell near a trial website.
These sufferers will then be directed to certainly one of Flatiron’s analysis websites, the place they are often introduced on as new sufferers and presumably enrolled in a medical trial using Flatiron’s proprietary know-how and consolidated affected person identification companies.
“Flatiron Well being is worked up to affix forces with Large Bio, combining experience and assets to advance personalised therapy choices for most cancers sufferers,” Michael Bierl, vice chairman of medical analysis partnerships and normal supervisor Europe at Flatiron Well being, mentioned in an announcement.
“By leveraging Large Bio’s strong community and database, we are able to proceed to make the most of our cutting-edge instruments to empower websites to progress analysis, improve workflows and efficiencies, speed up medical hint tempo whereas guaranteeing various affected person populations have entry to life-changing remedies which may in any other case be out of attain.”
Arturo Loaiza-Bonilla, cofounder and chief medical officer at Large Bio, mentioned the corporate’s mission is to make entry to medical trials patient-centric and assure the best affected person is matched to the best trial on the proper time, no matter the place they dwell.
“By pairing our AI-driven platform and concierge companies with Flatiron Well being’s intensive analysis infrastructure, we can assist physicians and care groups expedite trial enrollment, cut back disparities in entry and enhance outcomes for extra sufferers,” Loaiza-Bonilla mentioned in an announcement.
THE LARGER TREND
In March, the College of Colorado Most cancers Heart (CU Most cancers Heart) and Flatiron Well being joined forces to make medical trials extra productive by reducing the executive burden for researchers.
The partnership introduced Flatiron Medical Pipe to the CU Most cancers Heart and UCHealth, which allowed medical trial information to maneuver straight from digital well being information to digital information seize programs. The know-how additionally transfers info straight from the EHR to trial databases.
Flatiron Medical Pipe is an digital well being report to digital information seize connector that captures and transfers trial information.
That very same month, Flatiron collaborated with NRG Oncology, a medical analysis consortium within the Nationwide Most cancers Institute’s Nationwide Medical Trials Community, to make use of Flatiron Medical Pipe in a multicenter NRG medical trial.
In February, Flatiron partnered with Precise Sciences to extend medical proof technology for Precise Sciences’ molecular residual illness check Oncodetect. The alliance makes use of Flatiron’s medical analysis platform to guage a variety of strong tumor varieties.
The intention was to assemble medical proof in a real-world setting and disparate affected person populations through the use of group care settings which can be typically underrepresented in medical trials.
In January, DeepScribe partnered with Flatiron to carry DeepScribe’s AI documentation to clinicians who use Flatiron’s OncoEMR, a cloud-based digital medical report platform.
The alliance made DeepScribe the primary ambient AI answer companion for Flatiron Well being.
Final 12 months, Flatiron collaborated with the Affiliation of Most cancers Care Facilities (ACCC) to promote entry to medical trials in a group setting, increase medical examine effectivity and enhance the gathering of study-related information.
In 2022, Large Bio secured $9 million in financing. Revo Capital and Kenan Turnacioğlu led the spherical, with participation from DEG. The corporate used the funds to develop its operations globally, market itself and launch new merchandise.
